A Study to Evaluate CSJ148 in Pregnant Women With Primary HCMV Infection

Phase 2

Withdrawn

• Conditions: HCMV Infection
• Interventions: Biological: CSJ148; Other: Placebo

• Registration Number: NCT03369912
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

The purpose of the study is to evaluate the feasibility of using CSJ148 to prevent congenital human cytomegalovirus (HCMV) in pregnant women with primary HCMV infection.

Detailed Description

This is a randomized, patient, investigator and sponsor blinded, placebo-controlled study in pregnant women with primary HCMV infection. The study has three periods: (I) screening (II) double-blinded placebo-controlled treatment and (III) post-delivery follow-up of women and neonates/infants. Pregnant women with confirmed primary HCMV infection will participate in periods I and II. Mothers and neonates/infants born to mothers enrolled in the study will participate in period III.

Study Timeline

• Study First Submitted: 2017-11-28
• Study First Submitted QC: 2017-12-06
• Study First Posted: 2017-12-12
• Status Verified: 2018-10
• Last Update Submitted: 2018-10-05
• Last Update Posted: 2018-10-09
• Study Start: 2018-10-23
• Primary Completion: 2022-11-15
• Study Completion: 2022-11-15

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: Female
• Target Recruitment: Not specified

Inclusion Criteria

1. Written informed consent must be obtained before any assessment is performed.
2. Pregnant women ≥ 18 years of age with primary HCMV infection occurring between 6 and 24 weeks of gestation
3. Ability to receive study drug within 6 weeks of the presumed onset of primary maternal infection.
4. Able to communicate well with the investigator, to understand and comply with the requirements of the study.

Read More

Exclusion Criteria

1. Confirmed or suspected fetal HCMV infection, defined as positive HCMV DNA in amniotic fluid or fetal ultrasound abnormalities suggestive of fetal HCMV disease.
2. Prior treatment with any of the following within 30 days prior to enrollment: ganciclovir, valganciclovir, foscarnet, cidofovir, acyclovir (>25 mg/kg/day IV), valacyclovir (>3 gm/day oral), famciclovir (>1500 mg/day oral), HCMV immune globulin, immune globulin (>500 mg/kg), or any other medication with anti-HCMV activity.
3. Any surgical or medical condition (other than pregnancy) which might increase the risk for thrombotic events if the patient is given immune-globulins. These conditions include cryoglobulinemia, monoclonal gammopathies, and hypertriglyceridemia (fasting level >1000 mg/dL). The investigator should make this determination based on the patient's medical history and laboratory data.
4. History of chronic hepatitis B, hepatitis C and human immunodeficiency virus (HIV) infection. Cured hepatitis C in not considered exclusionary.
5. Patient request for medical interruption or termination of pregnancy before inclusion.
6. Any surgical or medical condition which may jeopardize the patient or fetus in case of participation in the study. The investigator should make this determination in consideration of the patient's obstetrical history.
7. Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer; or longer if required by local regulations.
8. History of hypersensitivity to any of the study treatments or excipients or to drugs of similar chemical classes.
9. Body weight > 100 kilograms.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Active	CSJ148	CSJ148
Placebo	Placebo	5% dextrose

Primary Outcome Measures

Name	Time	Method
Event rate of fetuses or neonates with congenital human cytomegalovirus (HCMV) infection	Day 218	To assess the efficacy of CSJ148 on reducing intrauterine HCMV transmission compared to placebo

Secondary Outcome Measures

Name	Time	Method
CSJ148 concentration in cord blood	Day 218	Concentration of CSJ148 (LJP538 and LJP539) in serum separated from cord blood
Immunogenicity of CSJ148 in pregnant women	Days 1,29,57,85,218,141,169, 197, 218	Detection of anti-LJP538 and anti-LJP539 antibodies in serum at selected timepoints
Immunogenicity of CSJ148 in cord blood	Day 218	Detection of anti-LJP538 and anti-LJP539 antibodies in serum from cord blood
CSJ148 concentration in amniotic fluid	Day 218	Concentration of CSJ148 (LJP538 and LJP539) in amniotic fluid
Change from Baseline in the Reduction in symptomatic congenital human cytomegalovirus (HCMV) disease (compared to placebo)	Day 218	Change in symptomatic HCMV disease, assessed by event rates in patients vs controls
Change from baseline in congenital human cytomegalovirus (HCMV) urine viral load in neonates at birth	Baseline, Day 218	Change in HCMV urine viral load in neonates at birth
Pharmacokinetic concentration data of CSJ148	Days 1,29,57,85,218,141,169, 197, 218	Concentration of CSJ148 (LJP538 and LJP539) in serum